Four regimens receive priority review for lung cancer indications

Issue: March 25, 2020

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA granted priority review to four anticancer therapies or combinations for the treatment of various subtypes of lung cancer.

These include:

• capmatinib (INC280; Novartis, Incyte), an investigational oral MET inhibitor, for the treatment of patients with advanced non-small cell lung cancer who harbor MET exon 14 skipping mutations;
• the combination of nivolumab (Opdivo, Bristol-Myers Squibb), an anti-PD-1 antibody, and ipilimumab (Yervoy, Bristol-Myers Squibb), an anti-CTLA-4 antibody, for the first-line treatment of patients with metastatic or recurrent NSCLC without EGFR or ALK mutations;
• lurbinectedin (PM1183; PharmaMar, Jazz Pharmaceuticals), an investigational RNA polymerase II inhibitor, for the treatment of small cell lung cancer that relapsed after platinum-based therapy; and
• selpercatinib (Eli Lilly) — formerly known as LOXO-292, an investigational oral agent for cancers that harbor abnormalities in the rearranged during transfection (RET) kinase — for the treatment of advanced RET fusion-positive NSCLC. The agent also received priority review for RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.